Viemed Healthcare, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 6, 2024. The filing also reports quarterly results, including Q4 2023. Dollar amounts below are U.S. dollars.
Business context
Viemed provides home medical equipment and post-acute respiratory care across all 50 states. Its services include ventilator and other equipment rentals, respiratory disease management, oxygen therapy, sleep apnea testing and treatment, and healthcare staffing. Ventilator rentals remain its largest revenue source. At year-end, it employed 996 people, including 372 licensed respiratory therapists.
Financial and operating highlights
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $183.0 million | $138.8 million |
| Gross profit / margin | $112.8 million / 61.6% | $84.7 million / 61.0% |
| Operating income / margin | $14.3 million / 7.8% | $8.3 million / 5.9% |
| Net income / net margin | $10.2 million / 5.6% | $6.2 million / 4.5% |
| Diluted EPS | $0.25 | $0.16 |
| Operating cash flow | $45.2 million | $27.7 million |
| Cash and cash equivalents at year-end | $12.8 million | $16.9 million |
Revenue increased 31.8%; excluding COVID-19 response revenue, it rose 34.0%. Growth included ventilator rentals (+16.8%), other equipment rentals (+78.7%), equipment and supply sales (+85.0%), and service revenue (+25.9%). FY 2023 Adjusted EBITDA, a non-GAAP measure, was $43.1 million; the company cautions that it should not be viewed as a substitute for GAAP results or cash flow.
In Q4 2023, revenue was $50.7 million, gross profit was $32.1 million (63% margin), net income was $3.5 million, and Adjusted EBITDA was $12.8 million. Active ventilator patients reached 10,327 at quarter-end.
Cash, debt, and liquidity
Operating cash flow was $45.2 million; investing used $52.1 million, including $28.6 million net cash paid for HMP and $26.1 million in property and equipment purchases. Financing provided $2.8 million, and cash declined by $4.1 million during the year. Total assets were $154.9 million and total liabilities $41.0 million at year-end.
Year-end debt included $4.9 million outstanding under the delayed-draw term loan and $2.0 million under the revolving facility; balance-sheet current and long-term debt were $1.1 million and $6.0 million, respectively. The facilities mature in November 2027, bear floating-rate pricing, and include leverage and fixed-charge covenants. Viemed reported compliance with its covenants at year-end. Management said cash, expected operating cash flows, and available credit were expected to fund operations, capital expenditures, and debt service for at least 12 months from the filing date.
Material changes, outlook, and risks
- HMP acquisition: Completed June 1, 2023, for approximately $29 million. HMP contributed $16.2 million of revenue and $1.3 million of pretax income after acquisition; the transaction added $29.8 million of goodwill.
- Management outlook: No specific revenue or earnings guidance is provided. Management expects gross margin to remain relatively stable, SG&A as a percentage of revenue to improve in 2024, R&D costs to remain broadly consistent, and net interest expense to decrease as acquisition-related debt is repaid.
- Reimbursement exposure: Medicare and Medicaid represented 46% of traditional revenue in 2023, versus 56% in 2022. Ventilator rentals represented approximately 59% of traditional revenue. Medicare’s 75/25 blended reimbursement rate expired on December 31, 2023; the company noted potential reimbursement pressure. CMS had not announced a new competitive-bidding round after the prior contracts expired.
- Supply and regulatory risks: The company relies on a limited number of equipment manufacturers. Philips announced in January 2024 that it would discontinue many respiratory products; Viemed also describes potential continuing legal and replacement-cost exposure from Philips’ device recall. Audits, documentation requirements, prior authorization, reimbursement changes, and healthcare fraud-and-abuse rules could affect collections and operations.
- Legal matters: In a dispute with Vyaire, a court found Vyaire had breached its contract; damages and Vyaire’s interlocutory appeal remained unresolved. Viemed reported that a potential loss on Vyaire’s $4.7 million counterclaim was not probable and that it had not accrued a liability. A separate OIG/MAC Medicare claims matter was resolved in Viemed’s favor, and funds previously remitted were received in 2023.
- Reporting and controls: Management concluded disclosure controls and internal control over financial reporting were effective. The auditor did not provide an ICFR attestation because the company was an emerging growth company. Viemed said it no longer qualified as a smaller reporting company and expected larger-company disclosure obligations to begin with its Q1 2024 Form 10-Q.
Important facts for investors to verify
- Whether growth outside ventilator rentals is recurring and improves the durability of revenue and margins.
- HMP integration, realized synergies, acquisition-related costs, and the performance of its acquired goodwill and assets.
- Actual effects of the expired Medicare blended rate, future CMS competitive bidding or prior-authorization decisions, and payor audits or recoupments.
- Equipment availability and any operational, legal, or financial consequences of Philips’ product discontinuations and recall.
- Debt repayment, floating-rate interest exposure, covenant headroom, and cash needs for rental-equipment purchases and future acquisitions.
- Developments in the Vyaire litigation and any other material legal, regulatory, or reimbursement contingencies.